Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women

► With daily teriparatide, bone markers peak after 6-12 months and then decline. ► We randomized osteoporotic women to constant or escalating dose teriparatide. ► Escalating dose teriparatide prevented the decline in bone turnover markers. ► Nonetheless, bone density increases were equivalent to constant dose teriparatide.